Your browser doesn't support javascript.
loading
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
Li, Jingxin; Hou, Lihua; Guo, Xiling; Jin, Pengfei; Wu, Shipo; Zhu, Jiahong; Pan, Hongxing; Wang, Xue; Song, Zhizhou; Wan, Jingxuan; Cui, Lunbiao; Li, Junqiang; Chen, Yin; Wang, Xuewen; Jin, Lairun; Liu, Jingxian; Shi, Fengjuan; Xu, Xiaoyu; Zhu, Tao; Chen, Wei; Zhu, Fengcai.
Afiliación
  • Li J; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Hou L; Institute of Global Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P. R. China.
  • Guo X; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China.
  • Jin P; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Wu S; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Zhu J; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China.
  • Pan H; Lianshui County Center for Disease Control and Prevention, Lianshui County, P. R. China.
  • Wang X; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Song Z; CanSino Biologics Inc., Tianjin, P. R. China.
  • Wan J; Lianshui County Center for Disease Control and Prevention, Lianshui County, P. R. China.
  • Cui L; CanSino Biologics Inc., Tianjin, P. R. China.
  • Li J; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Chen Y; CanSino Biologics Inc., Tianjin, P. R. China.
  • Wang X; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Jin L; Canming Medical Technology Co., Ltd, Shanghai, P. R. China.
  • Liu J; Department of Public Health, Southeast University, Nanjing, P. R. China.
  • Shi F; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Xu X; NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P. R. China.
  • Zhu T; Vazyme Biotech Co., Ltd, Nanjing, P. R. China.
  • Chen W; CanSino Biologics Inc., Tianjin, P. R. China.
  • Zhu F; Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P. R. China. cw0226@foxmail.com.
Nat Med ; 28(2): 401-409, 2022 02.
Article en En | MEDLINE | ID: mdl-35087233
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Inmunogenicidad Vacunal / Vacunas contra la COVID-19 / SARS-CoV-2 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Inmunogenicidad Vacunal / Vacunas contra la COVID-19 / SARS-CoV-2 / Anticuerpos Antivirales Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos